[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

# ![$10047share Graphic](https://lunarcrush.com/gi/w:26/t:$10047share.png) $10047share

iTeos ($ITOS) is being acquired by Concentra Biosciences for $10.047/share. The deal is expected to begin by August 1, 2025.

### About $10047share
A stock ticker symbol for iTeos Therapeutics.  

### Engagements: XXX [#](/topic/$10047share/interactions)
---
![Engagements Line Chart](https://lunarcrush.com/gi/w:600/t:$10047share/c:line/m:interactions.svg)  
[Engagements 24-Hour Chart Data](/topic/$10047share/time-series/interactions.tsv)  
**Current Value**: XXX  
**Daily Average**: XXX  
**1-Year High**: XXXXX on 2025-07-22  
**1-Year Low**: XX on 2025-07-26  

| Social Network | X   |
| -------------- | -   |
| Engagements    | XXX |
  

  
  
### Mentions: X [#](/topic/$10047share/posts_active)
---
![Mentions Line Chart](https://lunarcrush.com/gi/w:600/t:$10047share/c:line/m:posts_active.svg)  
[Mentions 24-Hour Chart Data](/topic/$10047share/time-series/posts_active.tsv)  
**Current Value**: X  
**Daily Average**: X  
**1-Year High**: X on 2025-07-25  
**1-Year Low**: X on 2025-07-21  

| Social Network | X |
| -------------- | - |
| Mentions       | X |
  

  
  
### Creators: X [#](/topic/$10047share/contributors_active)
---
![Creators Line Chart](https://lunarcrush.com/gi/w:600/t:$10047share/c:line/m:contributors_active.svg)  
[Creators 24-Hour Chart Data](/topic/$10047share/time-series/contributors_active.tsv)  
X unique social accounts have posts mentioning $10047share in the last XX hours which is up XX% from X in the previous XX hours
**Daily Average**: X  
**1-Year High**: X on 2025-07-25  
**1-Year Low**: X on 2025-07-21  

**Top topics mentioned**
In the posts about $10047share in the last XX hours

[$475m](/topic/$475m), [alternative investment](/topic/alternative-investment), [evo](/topic/evo), [$evo](/topic/$evo), [$itos](/topic/$itos), [$autl](/topic/$autl), [$ncna](/topic/$ncna), [$sabs](/topic/$sabs), [liquid](/topic/liquid), [tang](/topic/tang), [tax bracket](/topic/tax-bracket), [chapter 11](/topic/chapter-11)

### Top Social Posts [#](/topic/$10047share/posts)
---
Top posts by engagements in the last XX hours

*Showing only X posts for non-authenticated requests. Use your API key in requests for full results.*

"".the non-transferrable #contingent_value_right structure shifts risk to shareholders." #Concentra_Biosciences acquires #iTeos Payment: Upfront: $10.047/share #CVR: iTeos excess cash over $475M & XX% of 6mo iTeos net sales"  
[@bharatwrites](/creator/x/bharatwrites) on [X](/post/tweet/1948038940943900970) 2025-07-23 15:14:10 UTC XX followers, XX engagements


"📢 M&A News: Sanofi to acquire UK-based Vaccine Startup Vicebio 💸 $1.15B upfront + up to $450M in milestones. 🧪 Adds early-stage RSV + hMPV combo vaccine candidate (VXB-241) and 'Molecular Clamp' tech to pipeline. ❄ Molecular Clamp enables fully liquid fridge-stable vaccinesboosting efficiency distribution and prefilled syringe use. 📅 Deal expected to close in Q4 2025 See image for more details 👇"  
[@BiopharmIQ](/creator/x/BiopharmIQ) on [X](/post/tweet/1947667718326653152) 2025-07-22 14:39:04 UTC 25.8K followers, 3585 engagements


"As expected Kevin Tangs involvement was there for a reason. $ITOS is being acquired close to the conservative my liquidation value estimate with a cash offer of $10.047/share plus a CVR kicker: excess cash above $475M and XX% of the RemainCo pipeline assets. At the current run rate I dont see a meaningful case for distributions above $475M especially if the unrecognized tax liability is fully booked. That said below $10/share this was a decent optionality buy. Lets see how it plays out over the next few weeks with closing expected in Q3"  
[@InvestSpecial](/creator/x/InvestSpecial) on [X](/post/tweet/1947612164128178592) 2025-07-22 10:58:19 UTC 30K followers, 4917 engagements


"📢 M&A News: iTeos $ITOS Acquired by Concentra for $10.047/share + CVR🤝 💸 CVR includes XXX% of net cash $475M at closing + XX% of proceeds from asset sales within X months 📅 Deal expected to close Q3 2025 Check out our free biopharma M&A tracker 👇"  
[@BiopharmIQ](/creator/x/BiopharmIQ) on [X](/post/tweet/1947354268891287880) 2025-07-21 17:53:32 UTC 25.8K followers, 4562 engagements